Further work to delineate which mechanism of NF-κB inactivation by Wogonin for inhibition of transcription of Nrf2 offers the possibility of paving the way for the development of combination therapies more effective in the treatment of CML. This evidence concerns the gene NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive.